Navigation Links
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Date:7/14/2009

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body's own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs OFA to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

About Quantum Immunologics

Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives.

For more information about QI and its FDA-authorized trials, please visithttp://www.quantumimmunologics.com, or contact Investor Relations at (813) 849-7859.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    Contact:

    Timothy Schwiers
    Investor Relations
    813-849-7859

    Quantum Immunologics, Inc.
    2202 N. West Shore Blvd., Suite 200
    P.O. Box 20727
    Tampa, Florida 33623

This release was issued through eReleases(TM). For more information, visithttp://www.ereleases.com.


'/>"/>
SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
2. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
3. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
7. Immunotherapy-Based Provisional Patents Mark Significant Discovery
8. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
11. iCardiac Reports Significant Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... platforms, announced today that the company has engaged in a collaborative research partnership ... (MRDA) with the CSU Office of the Vice President for Research. This agreement ...
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
(Date:12/5/2016)... ... 2016 , ... This composition patent, U.S. Patent No. 9,499,637, ... composition claims are not limited to any particular process to make or use ... fibers, graphene, and other materials. A continuation application, U.S. Patent App. No. ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
Breaking Biology Technology:
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
Breaking Biology News(10 mins):